Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
CONTEXT: Type 2 diabetes (T2D) is reduced in postmenopausal women randomized to estrogen-based hormone therapy (HT) compared with placebo. Insulin sensitivity is a key determinant of T2D risk and overall cardiometabolic health, and studies indicate that estradiol (E2) directly impacts insulin action. OBJECTIVE: We hypothesized that the timing of E2 administration after menopause is an important determinant of its effect on insulin action. DESIGN: We performed a randomized, crossover, placebo-controlled study. PARTICIPANTS: Study participants were early postmenopausal (EPM; ≤ 6 years of final menses; n = 22) and late postmenopausal (LPM; ≥ 10 years since last menses; n = 24) women naive to HT. INTERVENTION: Study interventions included short-term (1 week) transdermal E2 and placebo. MAIN OUTCOMES AND MEASURES: The study's main outcome was insulin-mediated glucose disposal (glucose disposal rate [GDR]) via hyperinsulinemic-euglycemic clamp. RESULTS: Compared to EPM women, LPM women were older (mean ± SD; 63 ± 3 vs 56 ± 4 years, P < .05) and more years past menopause (12 ± 2 vs 3 ± 2 years, P < .05). Body mass index (24 ± 3 vs 25 ± 7 kg/m(2)) and fat mass (25 ± 7 vs 23 ± 6 kg) did not differ between groups, but fat-free mass (FFM) was lower in LPM women compared to EPM women (40 ± 4 vs 43 ± 5 kg, P < .05). Baseline GDR did not differ between groups (11.7 ± 2.8 vs 11.5 ± 2.9 mg/kg FFM/min). In support of our hypothesis, 1 week of E2 decreased GDR in LPM women compared to an increase in EPM women (+0.44 ± 1.7 vs - 0.76 ± 2.1 mg/kg FFM/min, P < .05). CONCLUSIONS: There was not an apparent decline in GDR with age or time since menopause per se. However, E2 action on GDR was dependent on time since menopause, such that there was an apparent benefit early (≤ 6 years) compared to harm later (≥ 10 years) in menopause. E2-mediated effects on insulin action may be one mechanism by which HT reduces the incidence of T2D in early postmenopausal women.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many studies have shown that E2 beneficially influences metabolism through mechanisms involving reduced food intake and increased energy expenditure (75, 129–131).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [131]
Citations
Cites
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Cornier, M.-A., Dabelea, D., Hernandez, T. L., Lindstrom, R. C., Steig, A. J., Stob, N. R., Van Pelt, R. E., Wang, H., & Eckel, R. H. (2008) · Endocrine Reviews · doi:10.1210/er.2008-0024 · Cited by 2,162
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Rossouw, J. E., Prentice, R. L., Manson, J. E., Wu, L., Barad, D., Barnabei, V. M., Ko, M., LaCroix, A. Z., Margolis, K. L., & Stefanick, M. L. (2007) · JAMA · doi:10.1001/jama.297.13.1465 · Cited by 1,741
The role of estrogens in control of energy balance and glucose homeostasis
Mauvais-Jarvis, F., Clegg, D. J., & Hevener, A. L. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1055 · Cited by 1,329
A survey for assessing physical activity among older adults
DIPIETRO, L., CASPERSEN, C. J., OSTFELD, A. M., & NADEL, E. R. (1993) · Medicine & Science in Sports & Exercise · doi:10.1249/00005768-199305000-00016 · Cited by 708
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Salpeter, S. R., Walsh, J. M. E., Ormiston, T. M., Greyber, E., Buckley, N. S., & Salpeter, E. E. (2006) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00545.x · Cited by 640
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00005 · Cited by 633
for the Women’s Health Initiative Investigators, Margolis, K. L., Bonds, D. E., Rodabough, R. J., Tinker, L., Phillips, L. S., Allen, C., Bassford, T., Burke, G., Torrens, J., et al. (2004) · Diabetologia · doi:10.1007/s00125-004-1448-x · Cited by 599
Grodstein, F., Manson, J. E., & Stampfer, M. J. (2006) · Journal of Women's Health · doi:10.1089/jwh.2006.15.35 · Cited by 479
Cited by
Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus
Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1137 · Cited by 2,043
Hormone-replacement therapy: current thinking
Lobo, R. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.164 · Cited by 484
Mauvais-Jarvis, F., Manson, J. E., Stevenson, J. C., & Fonseca, V. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1146 · Cited by 341
“Pereira (117) RCT 22 566 4 1 wk t-E2 50 mg Euglycemic, hyperinsulinemic clamp GDR ↑”
BackgroundHodis, H. N., & Mack, W. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000591 · Cited by 187
Sex Differences in Adipose Tissue Function
Gavin, K. M., & Bessesen, D. H. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.008 · Cited by 185
Metadata
- Authors
- Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., & Van Pelt, R. E.
- Affiliations
- Division of Geriatric Medicine; Department of Medicine (R.I.P., B.A.C.), Division of Endocrinology, Metabolism and Diabetes
- Department of Medicine (T.A.S., C.B.E., R.E.V.P.), Aurora, Colorado 80045
- Colorado School of Public Health (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-12-01
- Volume
- 100
- Issue
- 12
- Pages
- 4456-4462
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4667161
- OpenAlex
- W1680854225
- Cited by
- 59
- References
- 42
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 3 · 2019: 7 · 2018: 4 · 2017: 16 · 2016: 5
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute for Health and Care Research
- National Institutes of Health (UL1TR000154, UL1TR001082)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK088105, T32DK007446, P30DK048520)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD073063)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- estradiol, hormone therapy, menopause, insulin sensitivity, glucose disposal rate, type 2 diabetes risk, postmenopausal women, timing of hormone therapy, transdermal estradiol, fat-free mass, hyperinsulinemic-euglycemic clamp, cardiometabolic health, age at menopause, body composition, skeletal muscle
- MeSH terms
- Age Factors, Aged, Body Composition, Diabetes Mellitus, Type 2, Estradiol, Female, Glucose, Glucose Tolerance Test, Humans, Insulin Resistance, Middle Aged, Motor Activity, Glucose Clamp Technique, Estrogen Replacement Therapy, Body Mass Index, Treatment Outcome, Postmenopause, Cross-Over Studies, Risk Reduction Behavior, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action. https://app.cochat.ai/papers/10.1210/jc.2015-3084
- The paper
- Pereira, R. I., Casey, B. A., Swibas, T. A., Erickson, C. B., Wolfe, P., & Van Pelt, R. E. (2015). Timing of Estradiol Treatment After Menopause May Determine Benefit or Harm to Insulin Action. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2015-3084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.